This website uses cookies. These cookies allow us to recognize, distinguish and count the number of visitors to our site, helping us to provide you with a good experience while browsing our website. Please check the box to acknowledge the use of cookies. To find out more about this, please see our privacy policy.
Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., announced its decision to voluntarily withdraw OCALIVA® (obeticholic acid) from the US market for the treatment of primary biliary cholangitis (PBC), a rare, progressive liver disease.
Healthcare professionals can contact Medical Information at medinfo@interceptpharma.com or call 1-844-782-4278. Patients should talk to their healthcare professionals and may also contact Intercept's Patient Support Services (Interconnect) at 1-844-622-4278.
For all other inquiries please visit: https://www.interceptpharma.com/
Please click here for Full Prescribing Information and Medication Guide for OCALIVA.
Intercept does not control the content of this external site.
This site is intended for healthcare professionals from the U.S. only. Please select the option that best describes you.
Thank you for submitting your medical inquiry. In the event that you have any questions regarding your inquiry, please contact medinfo@interceptpharma.com.